EP162: Carving Out Specialty Drug Benefits With Pramod John, PhD, CEO at Vivio Health
Relentless Health Value™December 04, 2017
162
23:5832.92 MB

EP162: Carving Out Specialty Drug Benefits With Pramod John, PhD, CEO at Vivio Health

Pramod John is team leader of Vivio Health, a company that is reinventing the therapeutic use and supply chain for the specialty drug space.

The Vivio Health plan solution is challenging the current framework of efficacy and extending it to true effectiveness in the real world. It also offers significant drug acquisition savings and simplicity for the patient by integrating the supply chain into a unified and data driven process.

Prior to Vivio Health, Pramod was founder of Oration PBC (acquired by PokitDok) which was focused on giving back consumers control over their drug purchasing by capturing the prescription in the physician’s office and providing real-time pricing options and automatic routing capabilities. Pramod was also VP of Strategy and Innovation at McKesson, the world’s largest health care company. At McKesson, Pramod helped develop solutions that leveraged advanced technologies and business process improvements to optimize health care delivery systems, infrastructure, and supply chains.

Earlier, Pramod founded and served as CEO of PacketMotion, Inc., a venture-funded startup in the enterprise network information and policy management industry. The company was later acquired by VMware. In addition, Pramod founded netExaminer.com, a managed-vulnerability assessment company acquired by SonicWALL (owned by Dell).

Pramod earned his PhD in Electrical Engineering from the University of Illinois at Urbana-Champaign. He serves on the Boards of Mission Aviation Fellowship, a global relief organization, and 3Crosses Church in Castro Valley, CA. He also serves on the advisory board of Folia Water and as a mentor at StartX.


00:00 What aspects of health care that Vivio solves.
02:15 What would care look like by starting with the question, “What outcome do we want to see?”
04:40 Benefit designs.
06:00 Vivio’s customers.
06:50 How this works from the patient side.
09:00 How this looks from a clinician standpoint.
13:00 Proactively building clinical models and data collection.
13:30 Results of Vivio’s transparency.
14:45 How this comes down to a numbers problem.
15:00 “There’s very little clinical to do in a clinical trial.”
17:00 The types of reports that Vivio comes up with, and who they benefit?
19:00 “How do we help people see, ‘Here are the one or two things you need to understand.”
22:30 You can learn more at www.viviohealth.com.

digital,health,healthcare,marketing,pharma,tech,vivio,

Recent Episodes

EP445: Can a Primary-Care-Only Practice Survive in 2024? With Tom X. Lee, MD
July 25, 2024
445
47:5343.83 MB

EP445: Can a Primary-Care-Only Practice Survive in 2024? With Tom X. Lee, MD

In this healthcare podcast, I am talking with Tom X. Lee, MD, who has a long history in primary care. He founded One Medical and then also, most recently, Galileo. Dr. Lee also was a founder at Epocrates (tossing that in for context). For a full transcript of this episode, click here . If you enjoy...

Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes
July 18, 202434:1531.35 MB

Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes

Today is an encore because I am going on vacation next week. It always feels a little bit like a time warp because by the time this show will air, I will be back from vacation. This show with Paul Holmes was one of the most popular episodes of 2023 and definitely is just as relevant now. A lot of t...

EP444: Two State Healthcare Laws Often Don’t Go as Planned: CON and COPA, With Ann Kempski
July 11, 2024
444
35:1932.33 MB

EP444: Two State Healthcare Laws Often Don’t Go as Planned: CON and COPA, With Ann Kempski

Unintended consequences is a thing. ERCowboy wrote on Twitter a while back, “In any complex system, the likelihood of unintended consequences vastly outweighs the predictability of intended ones.” In this healthcare podcast, we’re talking about two state laws where this is apropos: CON (Certificate...

EP443: Let Us Never Pay the First Bill in Honor of Marshall Allen
July 04, 2024
443
36:1733.21 MB

EP443: Let Us Never Pay the First Bill in Honor of Marshall Allen

The first time I figuratively, not actually, met Marshall Allen was the day he did not meet Dave Chase for lunch. Dave was in Manhattan, and he was supposed to meet up with Marshall. But something happened, and Marshall was unable to make said lunch. So, I filled in for Marshall, who I had never me...

EP442: A Short Rumination on Saving Money, Except Not Saving Money. Oncology Side Effect Management as a Case Study, With Andreas Mang
June 27, 2024
442
18:5117.25 MB

EP442: A Short Rumination on Saving Money, Except Not Saving Money. Oncology Side Effect Management as a Case Study, With Andreas Mang

This week, I’m gonna play an outtake, I guess it could be called, from the show with Andreas Mang from Blackstone that we wound up cutting for reasons of time and topic; but it’s been on my mind ever since. So, here’s this clip; and then I’m gonna invite you to partake in my ruminations because the...

EP441: Tables Get Turned. This Is Me Interviewed by Abby Burns From Radio Advisory About What Is Value
June 20, 2024
441
40:3037.08 MB

EP441: Tables Get Turned. This Is Me Interviewed by Abby Burns From Radio Advisory About What Is Value

The show today is a recording of an earlier conversation between Abby Burns and myself. This original conversation happened during the Raising the Value Bar Summit, which was a summit all about value and the what, why, and how of it all. For a full transcript of this episode, click here . If you en...

EP440: What Is the Optimal Size for a Medical Practice? With David Muhlestein, PhD, JD
June 13, 2024
440
38:1535.01 MB

EP440: What Is the Optimal Size for a Medical Practice? With David Muhlestein, PhD, JD

Well, I reached out to David Muhlestein, PhD, JD, the other day to find out what he was up to since he left Leavitt Partners, which had been acquired by HMA, Health Management Associates. Answer: He’s building his own company in stealth mode. Stay tuned. For a full transcript of this episode, click...

Listen and Follow

Sponsored by Aventria Health Group
©2024 BD Bridges LLC. All Rights Reserved.